Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals develops cancer treatments that use its INTASYL RNA technology to help the immune system attack tumors. It last closed at $0.70 on Nov 17, down 6.88% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From PHIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on PHIO in the past 90 days. The average target is $14.00, with a high of $14.00 and a low of $14.00, compared with the last close of $0.70.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 26 | HC Wainwright & Co. | Reiterated | Buy | $14 |
Technical Analysis
The stock is 20% below its 20 day and 32% below its 50 day average. It is 53% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $0.70, and the nearest resistance the Pivot at $0.71.
| RSI (14) | 29.05 | Oversold below 30 | Oversold |
| MACD | -0.05 | Below its signal line | Bearish |
| Stochastic | 9.8 | Near the bottom of its range | Oversold |
| ADX (14) | 19.3 | No clear trend | |
| Williams %R | -100.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -200.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −22.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.06 | Typical daily range, 8.7% of price |
| RSI (14) | 26.82 | Oversold below 30 | Oversold |
| MACD | -0.10 | Below its signal line | Bearish |
| Stochastic | 4.9 | Near the bottom of its range | Oversold |
| ADX (14) | 21.3 | Weak trend | |
| Williams %R | -100.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -188.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −31.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.13 | Typical daily range, 18.1% of price |
What happened before
See how PHIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PHIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
Whale Options Flow
90DNo whale options trades in PHIO in the last 90 days.
PHIO Institutional Ownership
Full report →- ▲11 buying vs 9 selling
- ▲Held by funds +1.2 pts
- ▲Funds holding +2
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 26 | 24 | +8.3% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 6.6% | 5.4% | +1.2 pts |
| New / increased | 4 / 7 | 4 / 6 | +10.0% |
| Reduced / sold out | 7 / 2 | 8 / 4 | −25.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHIO is in one of them and how their past PHIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PHIO in an article yet. Here's the latest on the wider market.
About Phio Pharmaceuticals
Phio Pharmaceuticals is a clinical stage biopharmaceutical company based in King of Prussia, Pennsylvania. It is developing cancer treatments based on its INTASYL small interfering RNA technology, which is designed to silence proteins that reduce the immune system's ability to attack tumors. Its lead candidate, PH-762, is being tested in a clinical trial in patients with skin cancers, including cutaneous squamous cell carcinoma and melanoma. The therapies are designed for patients with cancer and are given by injection directly into tumors.
- Headquarters
- King Of Prussia, PA

